Upgrade to SI Premium - Free Trial

Goldman Sachs Starts Neurocrine Bio. (NBIX) at Buy

December 13, 2018 4:54 AM
Goldman Sachs analyst Paul Choi initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot New Coverage New Coverage

Next Articles